According to Sinopharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 6.52573. At the end of 2022 the company had a P/E ratio of 6.45.
Year | P/E ratio | Change |
---|---|---|
2022 | 6.45 | 17.28% |
2021 | 5.50 | -17.02% |
2020 | 6.62 | -45.23% |
2019 | 12.1 | -13.26% |
2018 | 13.9 | -7.33% |
2017 | 15.0 | -11.43% |
2016 | 17.0 | -10.03% |
2015 | 18.9 | -3.44% |
2014 | 19.6 | 0.02% |
2013 | 19.5 | -18.75% |
2012 | 24.1 | 5.26% |
2011 | 22.9 | -47.83% |
2010 | 43.8 | -4.59% |
2009 | 45.9 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.